Monte Rosa Therapeutics Inc (GLUE) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access GLUE Annual Balance Sheets →
Balance sheet performance over multiple periods helps investors evaluate the financial resilience of Monte Rosa Therapeutics Inc.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent159.86
Marketable Securities, Total MA506.36
Cash & Short-term Investments665.00
Other Receivables4.61
Other Current Assets0.00
Prepaid Expense And Other Assets Current6.72
Total Current Assets677.55
Equipment/Property/Plant Net28.41
Other Assets, Noncurrent30.47
Collaboration Receivable Current-
Restricted Cash Noncurrent4.95
Total Assets736.43
Liabilities
Accounts Payable, Current AC7.90
Other Liabilities, Current0.00
Deferred Liability and Revenue103.64
Total Current Liabilities111.54
Total Long-term Debt0.00
Defined Benefit Pension Plan, Liabilities, Noncurrent PE5.26
Other liabilities, Noncurrent97.72
Operating Lease Liability Current4.48
Total Liabilities214.51
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock1,048.37
Retained Earnings / Accumulated Deficit-521.72
Other Equity-4.75
Common Stockholder's Equity521.92
Total Stockholder's Equity521.92
Liabilities & Stockholder's Equity736.43
4 historic quarters locked

Sign in to unlock the full Monte Rosa Therapeutics Inc balance sheet history.

About Monte Rosa Therapeutics Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-336711

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.